The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Soliqua 100/33 contains two active ingredients, insulin glargine and lixisenatide. (An active ingredient is what makes a medication work.) Each active ingredient has its own mechanism of action ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

In the present study, we investigated mechanisms by which high SHBG may prevent development to diabetes. Conclusions—Possible mechanisms by which high circulating SHBG prevents the development ...

A catalytic mechanism is the sequence of elementary reactions by which a catalytic reaction proceeds. The behaviour of nanoconfined water can be very different from that of the bulk and is ...

The international team describes their results and the underlying molecular mechanism in Cell Metabolism. Ergothioneine is a natural compound found in certain fungi such as oyster or shiitake ...

"These findings illuminate a critical mechanism that connects local synaptic activity to the broader gene expression changes necessary for learning and memory," said Mark Dell'Acqua, professor of ...

Defense mechanisms are rooted in Freud’s theory of personality.According to his model, the mind has three dueling forces: the id (unconscious and primitive urges for food, comfort, and sex), the ...

When a GLP-1 drug similar to Ozempic helped slow Parkinson's symptoms A recent New England Journal of Medicine study tested lixisenatide, a GLP-1 drug, as a potential treatment for early-stage ...